(Q21260390)

English

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

scientific article

In more languages

Statements

scholarly article

0 references

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells (English)

0 references

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Roman A Blaheta

8

object named as

Roman A Blaheta

author given names

Roman A

author last names

Blaheta

1 reference

Dimensions Publication ID

18 August 2022

author name string

Eva Juengel

1

author given names

Eva

author last names

Juengel

1 reference

Dimensions Publication ID

18 August 2022

Johanna Engler

2

author given names

Johanna

author last names

Engler

1 reference

Dimensions Publication ID

18 August 2022

Iyad Natsheh

3

author given names

Iyad

author last names

Natsheh

1 reference

Dimensions Publication ID

18 August 2022

Jon Jones

4

author given names

Jon

author last names

Jones

1 reference

Dimensions Publication ID

18 August 2022

Ausra Mickuckyte

5

author given names

Ausra

author last names

Mickuckyte

1 reference

Dimensions Publication ID

18 August 2022

Lukasz Hudak

6

author given names

Lukasz

author last names

Hudak

1 reference

Dimensions Publication ID

18 August 2022

Dietger Jonas

7

author given names

Dietger

author last names

Jonas

1 reference

Dimensions Publication ID

18 August 2022

language of work or name

0 references

publication date

2009

0 references

0 references

9

0 references

1

0 references

161

0 references

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

19 March 2017

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

19 March 2017

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

7 April 2017

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

Application of IL-2 and other cytokines in renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

12 September 2017

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

27 September 2017

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

Bromodeoxyuridine induces p53-dependent and -independent cell cycle arrests in human gastric carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-161

21 January 2018

Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

29 November 2018

Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

29 November 2018

Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693528

29 November 2018

Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19473483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the mTOR signaling pathway in renal clear cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19473483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19473483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19473483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D

1 reference

https://pubmed.ncbi.nlm.nih.gov/19473483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-9-161

0 references

Dimensions Publication ID

0 references

release_wyulbx3yergkpcssydsl55ffa4

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21260390&oldid=2176723555"